Objective:To explore the effect of Yifei-Huoxue Decoction combined with conventional western medicine on patients with oxidant-antioxidant imbalance with COPD. Methods:A total of 102 patients who met the inclusion criteria from January 2016 to December 2018 were divided into two groups, according to the random table method, 51 cases in each group. The control group was treated with conventional western medicine, while the research group was treated with Yifei-Huoxue Decoction based on control group. Both the two groups were treated for 14 days. The traditional Chinese medicine symptom scores of the two groups were compared before and after the treatment. The forced expiratory volume in one second/predicted value ratio (FEV1%pred) was measured by pulmonary function instrument, FEV1/forced vital capacity (FVC) was calculated. Partial pressure of oxygen (PaO 2) and partial pressure of carbon dioxide (PaCO 2) were measured by blood gas analyzer. The levels of MDA, SOD and Glutathioneperoxidase (GSH-Px) were detected by ELISA, and the clinical effect was evaluated. Results:The total effective rate of research group was 98.0% (50/51), the control group was 80.4% (41/51), and the difference between the two groups was statistically significant ( χ2=8.254, P=0.004). After the treatment, the scores of cough, expectoration, asthma, panic, chest distress and fatigue in the research group were significantly lower than those of the control group ( t values were 3.716, 6.524, 5.032, 2.516, 4.804 and 2.882, respectively, all Ps<0.05). After the treatment, the FEV1%pred (68.05% ± 6.11% vs. 59.02% ± 5.45%, t=7.876), FEV1/FVC (60.10 ± 5.83 vs. 54.05 ± 5.07, t=5.592), PaO 2 (67.79 ± 3.82 mmHg vs. 60.63 ± 3.55 mmHg, t=9.805) in the research group were significantly higher than those of the control group ( P<0.05), the PaCO 2 (56.08 ± 2.25 mmHg vs. 61.14 ± 2.13 mmHg, t=11.663) was significantly lower than that of the control group ( P<0.01), the levels of serum MDA (3.21 ± 0.63 μmol/L vs. 4.95 ± 0.87 μmol/L, t=11.568) was significantly lower than that of the control group ( P<0.01), the levels of SOD (73.35 ± 8.97 μU/ml vs. 61.68 ± 7.82 μU/ml, t=7.003), GSH-Px (170.35 ± 17.72 U/ml vs. 149.14 ± 15.04 U/ml, t=6.517) were significantly higher than those of the control group ( P<0.01). Conclusions:The Yifei-Huoxue Decoction combined with conventional western medicine could improve the lung function of children with COPD , adjust the imbalance condition of oxidation/antioxidation, so as to improve the clinical effect.

Objective: To study the effect of doxofylline on acute exacerbation of chronic obstructive pulmonary disease (COPD) and reduce the risk of early recurrence. Methods: From January 2016 to January 2018, 164 patients with acute exacerbation of COPD in Binzhou Central Hospital were randomly divided into two groups by random digital table: control group (n=82) and observation group (n=82). The control group was given tiotropium bromide and budesonide/formoterol.The observation group was treated with oral doxophylline bid for 8 weeks on the basis of inhaled drugs.The recovery time, acute exacerbation rate, FEV₁, CAT score and 6-minute walking test were compared between the two groups. Results: The time of convalescent stage in the observation group was shorter than that in the control group[(16.89±5.15)d vs.(19.12±6.29)d, t=2.48, P=0.014], and the acute exacerbation rate of the observation group was lower than that of the control group (26.83% vs.41.46%, χ²=4.58, P=0.032). There was no statistically significant difference in FEV₁[(45.59±9.82)% vs.(44.26±9.03)%, t=0.90, P=0.369], and the CAT score of the observation group was better than that of the control group [(19.32±6.16)points vs.(21.71±6.62)points, t=2.39, P=0.018]. The 6-minute walking distance of the observation group was longer than that of the control group[(146.32±10.20)m vs.(135.69±11.59)m, t=6.23, P=0.000], and the finger pulse oxygen of the observation group was higher than that of the control group[(94.12±5.09)% vs.(92.06±6.21)%, t=2.23, P=0.026]. The respiratory rate in the observation group was slower than that in the control group[(20.38±7.32)times/min vs.(22.86±6.53)times/min, t=2.29, P=0.023], and there was no statistically significant difference in heart rate[(98.24±12.35)bpm vs.(101.38±15.03)bpm, t=1.46, P=0.146]. No serious adverse drug reactions were found in both two groups. Conclusion As a beneficial supplement of inhaled drugs in convalescent COPD, doxofylline can shorten the recovery time, reduce the early acute exacerbation rate and improve the symptoms, which is worthy of clinical reference.

Clinical trial management system is independently developed by our hospital, which basically realized the whole process management and data collection of clinical trials. Based on the platform, the functional architecture of data remote monitoring and auditing was established. By desensitizing and encrypting of data, the project and subject hologram were visualized to facilitate to review of data. The data remote monitoring and auditing cloud platform adopts the B/S architecture pattern. Users register to apply for an account through the cloud platform, and access to the account via HTTPS security protocol. The authorized users were able to view the relevant items online to ensure the secure data transmission and easy operating. The electronic management of data is the direction of future efforts. By compliance with laws and regulations, the remote monitoring/auditing can be realized, and the data security and personal privacy can be ensured with the application of information technology. In this paper, the feasibility of remote monitoring/auditing mode is explored, specific technical schemes and system functions are suggested, and the realization scenarios are conceived in case of major public health emergencies.